tiprankstipranks
Trending News
More News >
BNB Plus (BNBX)
NASDAQ:BNBX

BNB Plus (BNBX) AI Stock Analysis

Compare
987 Followers

Top Page

BNBX

BNB Plus

(NASDAQ:BNBX)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
$0.74
▼(-49.80% Downside)
Action:ReiteratedDate:03/08/26
The score is held down primarily by weak financial performance (shrinking revenue, heavy losses, and ongoing cash burn) and bearish technicals (price below all major moving averages with negative MACD). Low balance-sheet leverage provides some offset, while corporate events are modestly positive but include potential dilution considerations; valuation is constrained by negative earnings and no dividend.
Positive Factors
Low leverage
Very low debt-to-equity (~0.08) reduces near-term solvency and interest burden, giving management time to execute strategy or raise capital without immediate default risk. This structural balance-sheet cushion supports operations while the company addresses revenue and cash-flow challenges.
Positive gross margin
A positive gross margin (~28%) indicates the core offering retains markup over direct costs, implying an intrinsic business economics that can scale. If revenue stabilizes and cost controls improve, gross-profit leverage can restore operating profitability over the medium term.
Board adds crypto/DeFi expertise
Adding a seasoned digital-asset director strengthens strategic decision-making, governance and industry networks. This structural upgrade can accelerate product-market fit in BNB treasury and DeFi yield initiatives, improving execution odds and partnership access over the coming months.
Negative Factors
Shrinking revenue
A 23.5% TTM revenue decline signals weakening demand or loss of commercial traction. Sustained top-line contraction undermines scale economics, pressures gross and operating margins, and lengthens the path to break-even absent product, pricing or distribution improvements.
Ongoing cash burn
Material negative operating and free cash flow means the company consumes cash faster than it generates it, forcing reliance on external financing. Over a multi-month horizon this raises dilution risk, limits strategic investments, and compresses runway unless revenue or cash conversion improves.
Negative margins & returns
Persistently negative EBIT and net margins alongside a negative ROE indicate the business is not generating shareholder returns and is destroying equity value. This structural underperformance harms reinvestment capacity, creditor confidence and long-term viability until margins reverse.

BNB Plus (BNBX) vs. SPDR S&P 500 ETF (SPY)

BNB Plus Business Overview & Revenue Model

Company DescriptionBNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
How the Company Makes Moneynull

BNB Plus Financial Statement Overview

Summary
Financials are dominated by declining TTM revenue (-23.52%), deep losses (EBIT margin -6.03%, net margin -5.65%), and continued cash burn (TTM operating cash flow -$14.7M; free cash flow -$14.9M). Low leverage (debt-to-equity ~0.08) helps near-term solvency, but negative returns (ROE -1.85%) and weak cash generation keep the financial profile fragile.
Income Statement
14
Very Negative
TTM (Trailing-Twelve-Months) revenue declined (-23.52%) and profitability remains deeply negative, with large operating losses (EBIT margin -6.03%) and a very weak net margin (-5.65%). Gross margin is positive (28.45%), but it has compressed versus the latest annual period (39.26%), suggesting weaker pricing/mix or higher costs. Overall, the business is not close to operating break-even and results have worsened versus the prior year annual net margin (-2.04%).
Balance Sheet
62
Positive
Leverage is low, with modest debt relative to equity (debt-to-equity ~0.08 in both TTM (Trailing-Twelve-Months) and the latest annual period), which reduces near-term solvency risk. However, shareholder returns are sharply negative (TTM return on equity -1.85%), reflecting significant losses. The balance sheet provides some cushioning, but persistent losses can pressure equity over time if funding needs continue.
Cash Flow
18
Very Negative
Cash generation is weak with materially negative operating cash flow (TTM (Trailing-Twelve-Months) -$14.7M) and negative free cash flow (TTM -$14.9M), indicating ongoing cash burn. While free cash flow growth is reported positive in TTM (16.38%), absolute cash flow remains meaningfully negative, implying continued reliance on external financing. A positive free cash flow to net income ratio (~1.03) mainly reflects that both figures are negative rather than healthy cash conversion.
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue2.05M2.14M3.43M13.37M18.17M9.03M
Gross Profit474.56K838.91K1.02M5.53M5.05M4.93M
EBITDA-26.27M-15.66M-13.33M-9.59M-12.68M-11.68M
Net Income-31.11M-15.16M-6.99M-9.95M-8.38M-16.03M
Balance Sheet
Total Assets20.70M4.44M12.79M13.65M22.27M14.42M
Cash, Cash Equivalents and Short-Term Investments2.45M1.67M6.43M7.15M15.22M6.55M
Total Debt48.86K193.25K739.16K1.24M0.000.00
Total Liabilities2.24M2.50M3.82M8.78M9.36M3.30M
Stockholders Equity18.84M2.30M9.14M4.95M12.91M11.11M
Cash Flow
Free Cash Flow-15.12M-12.83M-14.12M-6.30M-9.47M-15.94M
Operating Cash Flow-14.92M-12.52M-13.71M-6.22M-8.98M-13.39M
Investing Cash Flow-3.14M-292.12K-407.90K-1.10M-489.55K-2.55M
Financing Cash Flow11.06M8.05M13.40M0.0018.13M14.70M

BNB Plus Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.48
Price Trends
50DMA
1.08
Negative
100DMA
1.95
Negative
200DMA
3.08
Negative
Market Momentum
MACD
-0.09
Negative
RSI
42.38
Neutral
STOCH
91.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 1.08, and below the 200-day MA of 3.08, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 42.38 is Neutral, neither overbought nor oversold. The STOCH value of 91.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.

BNB Plus Risk Analysis

BNB Plus disclosed 41 risk factors in its most recent earnings report. BNB Plus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BNB Plus Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
48
Neutral
$9.23M-0.13
44
Neutral
$5.82M-0.85-197.93%3.26%65.96%
42
Neutral
$4.28M-0.15-259.18%-21.79%86.75%
42
Neutral
$3.98M-0.64-537.60%98.86%
41
Neutral
$1.95M-0.68-296.20%-67.73%58.35%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BNBX
BNB Plus
0.79
-29.22
-97.38%
NDRA
ENDRA Life Sciences
3.41
-0.54
-13.67%
INBS
Intelligent Bio Solutions
3.63
-18.07
-83.27%
ISPC
iSpecimen
0.20
-1.13
-84.96%
BGLC
BioNexus Gene Lab Corp
2.51
-0.58
-18.64%
MYNZ
Mainz Biomed B.V.
0.74
-3.53
-82.74%

BNB Plus Corporate Events

Business Operations and StrategyExecutive/Board Changes
BNB Plus Appoints Digital Asset Veteran to Board
Positive
Feb 5, 2026

On February 2, 2026, BNB Plus Corp. filled a board vacancy created by the resignation of a prior director by appointing digital asset veteran James Haft as an independent director and member of its Nominating Committee, a move announced publicly on February 5, 2026. Haft’s compensation package includes a $40,000 cash fee and stock options for 93,000 shares vesting over four dates through February 2, 2027, along with eligibility for future equity grants and coverage under the company’s standard indemnification agreement. With more than 35 years of experience across blockchain infrastructure, emerging markets and traditional finance, and a track record that includes founding digital-asset-focused merchant banking and blockchain education platforms, Haft is expected to bolster BNB Plus’s governance and strategic expertise as it scales its BNB treasury operations and DeFi yield capabilities, while the company has disclosed that his only related-party connection is an arm’s-length investment in an October 2025 PIPE by a fund co-founded by his son in which Haft has no management role.

Executive/Board Changes
BNB Plus Announces Routine Board Director Resignation
Neutral
Jan 22, 2026

On January 15, 2026, BNB Plus Corp. announced that director Elizabeth M. Schmalz Shaheen resigned from the company’s board, effective immediately. The company stated that her departure did not stem from any disagreement regarding its operations, policies or practices, suggesting the change reflects a routine governance transition rather than signaling strategic or operational conflict for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 08, 2026